PMID- 32737420
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1476-5608 (Electronic)
IS  - 1365-7852 (Print)
IS  - 1365-7852 (Linking)
VI  - 24
IP  - 1
DP  - 2021 Mar
TI  - Cardiac biomarkers in patients with prostate cancer and cardiovascular disease 
      receiving gonadotrophin releasing hormone agonist vs antagonist.
PG  - 177-185
LID - 10.1038/s41391-020-0264-9 [doi]
AB  - BACKGROUND: Gonadotrophin releasing hormone (GnRH) agonists and antagonists 
      reduce testosterone levels for the treatment of advanced and metastatic prostate 
      cancer. Androgen deprivation therapy (ADT) is associated with increased risk of 
      cardiovascular (CV) events and CV disease (CVD), especially in patients with 
      preexisting CVD treated with GnRH agonists. Here, we investigated the potential 
      relationship between serum levels of the cardiac biomarkers N-terminal pro-B-type 
      natriuretic peptide (NTproBNP), D-dimer, C-reactive protein (CRP), and 
      high-sensitivity troponin (hsTn) and the risk of new CV events in prostate cancer 
      patients with a history of CVD receiving a GnRH agonist or antagonist. METHODS: 
      Post-hoc analyses were performed of a phase II randomized study that 
      prospectively assessed CV events in patients with prostate cancer and preexisting 
      CVD, receiving GnRH agonist or antagonist. Cox proportional hazards models were 
      used to determine whether the selected biomarkers had any predictive effect on CV 
      events at baseline and across a 12-month treatment period. RESULTS: Baseline and 
      disease characteristics of the 80 patients who took part in the study were well 
      balanced between treatment arms. Ischemic heart disease (66%) and myocardial 
      infarction (37%) were the most common prior CVD and the majority (92%) of 
      patients received CV medication. We found that high levels of NTproBNP 
      (p = 0.008), and hsTn (p = 0.004) at baseline were associated with the 
      development of new CV events in the GnRH agonist group but not in the antagonist. 
      In addition, a nonsignificant trend was observed between higher levels of 
      NTproBNP over time and the development of new CV events in the GnRH agonist 
      group. CONCLUSIONS: The use of cardiac biomarkers may be worthy of further study 
      as tools in the prediction of CV risk in prostate cancer patients receiving ADT. 
      Analysis was limited by the small sample size; larger studies are required to 
      validate biomarker use to predict CV events among patients receiving ADT.
FAU - Margel, David
AU  - Margel D
AD  - Division of Urology, Rabin Medical Center, Petach Tikva, Israel. 
      sdmargel@gmail.com.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 
      sdmargel@gmail.com.
FAU - Ber, Yaara
AU  - Ber Y
AD  - Division of Urology, Rabin Medical Center, Petach Tikva, Israel.
FAU - Peer, Avivit
AU  - Peer A
AD  - Department of Oncology, Rambam Health Care Campus, Haifa, Israel.
AD  - Rappaport Faculty of Medicine, Technion, Haifa, Israel.
FAU - Shavit-Grievink, Liat
AU  - Shavit-Grievink L
AD  - Division of Urology, Rabin Medical Center, Petach Tikva, Israel.
AD  - Davidoff Cancer Centre, Rabin Medical Center, Petach Tikva, Israel.
FAU - Pinthus, Jehonathan H
AU  - Pinthus JH
AD  - Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, 
      Canada.
FAU - Witberg, Guy
AU  - Witberg G
AD  - Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel.
FAU - Baniel, Jack
AU  - Baniel J
AD  - Division of Urology, Rabin Medical Center, Petach Tikva, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Kedar, Daniel
AU  - Kedar D
AD  - Division of Urology, Rabin Medical Center, Petach Tikva, Israel.
FAU - Rosenbaum, Eli
AU  - Rosenbaum E
AD  - Davidoff Cancer Centre, Rabin Medical Center, Petach Tikva, Israel.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - England
TA  - Prostate Cancer Prostatic Dis
JT  - Prostate cancer and prostatic diseases
JID - 9815755
RN  - 0 (Biomarkers)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Peptide Fragments)
RN  - 0 (Troponin)
RN  - 0 (fibrin fragment D)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/*blood/etiology
MH  - Fibrin Fibrinogen Degradation Products/*metabolism
MH  - Follow-Up Studies
MH  - Gonadotropin-Releasing Hormone/*agonists/*antagonists & inhibitors
MH  - Humans
MH  - Male
MH  - Myocardium/metabolism
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Prostatic Neoplasms/blood/*drug therapy
MH  - Troponin/*blood
PMC - PMC8012206
COIS- DM and JHP have received honoraria and research grants from Ferring 
      Pharmaceuticals. All other authors have no conflicts of interest to declare.
EDAT- 2020/08/02 06:00
MHDA- 2021/11/25 06:00
PMCR- 2020/07/31
CRDT- 2020/08/02 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/07/12 00:00 [revised]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/07/31 00:00 [pmc-release]
AID - 10.1038/s41391-020-0264-9 [pii]
AID - 264 [pii]
AID - 10.1038/s41391-020-0264-9 [doi]
PST - ppublish
SO  - Prostate Cancer Prostatic Dis. 2021 Mar;24(1):177-185. doi: 
      10.1038/s41391-020-0264-9. Epub 2020 Jul 31.